Exploring alternative dosing regimens of single-agent belantamab mafodotin on safety and efficacy in patients with relapsed or refractory multiple myeloma: DREAMM-14.

被引：0
|
作者：
Hultcrantz, Malin
Kleinman, David
Ghataorhe, Pavandeep
McKeown, Astrid
He, Wei
Ling, Thomas
Jewell, Roxanne C.
Byrne, Julie
Eliason, Laurie
Scott, Emma Catherine
Opalinska, Joanna
机构：
[1] Mem Sloan Kettering Canc Ctr, Myeloma Serv, Dept Med, New York, NY USA
[2] Univ Rochester, Rochester, NY USA
[3] GlaxoSmithKline, London, England
[4] GlaxoSmithKline, Boston, MA USA
[5] GlaxoSmithKline, Res Triangle Pk, NC USA
[6] GlaxoSmithKline, Upper Providence, PA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2022年 / 40卷 / 16期
基金：
芬兰科学院;
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS8073
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Exploring Alternative Dosing Regimens of Single-Agent Belantamab Mafodotin on Safety and Efficacy in Patients with Relapsed or Refractory Multiple Myeloma: DREAMM-14
    Hultcrantz, Malin
    Kleinman, David
    Ghataorhe, Pavandeep
    McKeown, Astrid
    He, Wei
    Ling, Thomas
    Jewell, Roxanne C.
    Brunner, Joseph
    Byrne, Julie
    Eliason, Laurie
    Scott, Emma
    Opalinska, Joanna
    BLOOD, 2021, 138
  • [2] Exploring Alternative Dosing Regimens of Single-Agent Belantamab Mafodotin on Safety and Efficacy in Patients With Relapsed or Refractory Multiple Myeloma (RRMM): DREAMM-14
    Salwender, Hans
    Hultcrantz, Malin
    Kleinman, Dave
    Ghataorhe, Pavandeep
    Mckeown, Astrid
    He, Wei
    Ling, Thomas
    Jewell, Roxanne
    Byrne, Julie
    Eliason, Laurie
    Scott, Emma
    Opalinska, Joanna
    ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (SUPPL 3) : 174 - 174
  • [3] Exploring Alternative Dosing Regimens of Single-Agent Belantamab Mafodotin on Safety and Efficacy in Patients With Relapsed or Refractory Multiple Myeloma (RRMM): DREAMM-14
    Hultcrantz, Malin
    Kleinman, David
    Ghataorhe, Pavandeep
    McKeown, Astrid
    He, Wei
    Ling, Thomas
    Jewell, Roxanne C.
    Byrne, Julie
    Eliason, Laurie
    Scott, Emma
    Opalinska, Joanna
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S425 - S425
  • [4] Single-Agent Belantamab Mafodotin in Patients with Relapsed or Refractory Multiple Myeloma: Final Analysis of the DREAMM-2 Trial
    Nooka, Ajay K.
    Cohen, Adam
    Lee, Hans C.
    Badros, Ashraf Z.
    Suvannasankha, Attaya
    Callander, Natalie
    Abdallah, Al-Ola
    Trudel, Suzanne
    Chari, Ajai
    Libby, Edward
    Chaudhry, Maria
    Hultcrantz, Malin
    Kortuem, Martin
    Richardson, Paul G.
    Popat, Rakesh
    Sborov, Douglas W.
    Hakim, Shawn
    Lewis, Eric
    Bhushan, Bharat
    Gorsh, Boris
    Gupta, Ira
    Opalinska, Joanna
    Lonial, Sagar
    BLOOD, 2022, 140 : 7301 - 7303
  • [5] Single-agent belantamab mafodotin in patients with relapsed/refractory multiple myeloma: Final analysis of the DREAMM-2 trial
    Ramasamy, Karthik
    Nooka, Ajay
    Cohen, Adam
    Lee, Hans
    Badros, Ashraf
    Suvannasankha, Attaya
    Callander, Natalie
    Abdallah, Al-Ola
    Trudel, Suzanne
    Chari, Ajai
    Libby, Edward
    Chaudhry, Maria
    Hultcrantz, Malin
    Kortuem, K. Martin
    Richardson, Paul
    Popat, Rakesh
    Sborov, Douglas
    Hakim, Shawn
    Lewis, Eric
    Bhushan, Bharat
    Gorsh, Boris
    Gupta, Ira
    Opalinska, Joanna
    Lonial, Sagar
    BRITISH JOURNAL OF HAEMATOLOGY, 2023, 201 : 68 - 69
  • [6] Safety, pharmacokinetics, and efficacy of belantamab mafodotin monotherapy in Japanese patients with relapsed or refractory multiple myeloma: DREAMM-11
    Iida, Shinsuke
    Sunami, Kazutaka
    Mishima, Yuko
    Fujii, Taku
    Kato, Hitomi
    Terao, Takumi
    Matsuzawa, Yuki
    Matsubara, Mari
    Crossman, Timothy
    Kremer, Brandon E.
    Gupta, Ira
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2023, 118 (05) : 596 - 608
  • [7] Safety and efficacy of belantamab mafodotin with pembrolizumab in patients with relapsed or refractory multiple myeloma
    Suvannasankha, Attaya
    Bahlis, Nizar
    Trudel, Suzanne
    Weisel, Katja
    Koenecke, Christian
    Oriol, Albert
    Voorhees, Peter M.
    Alonso, Aranzazu A.
    Callander, Natalie S.
    Mateos, Maria-Victoria
    Reddy, Nishitha
    Hakim, Shawn
    Lamacchia, John
    Patel, Nashita
    Williams, Danae
    Jewell, Roxanne. C.
    Zhou, Xiangdong
    Gupta, Ira
    Opalinska, Joanna
    Nooka, Ajay K.
    CANCER, 2024, 130 (15) : 2629 - 2641
  • [8] DREAMM-2: Single-agent belantamab mafodotin (GSK2857916) in patients with relapsed/refractory multiple myeloma (RRMM) and renal impairment
    Kortuem, M.
    Lee, H. C.
    Cohen, A. D.
    Chari, A.
    Hultcrantz, M.
    Nooka, A. K.
    Callander, N.
    Suvannasankha, A.
    Badros, A.
    Libby, E.
    Trudel, S.
    Richardson, P.
    Sborov, D.
    Rodriguez Otero, P.
    Lonial, S.
    Zhi, E.
    Lewis, E.
    Gupta, I
    Opalinska, J.
    ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 (SUPPL 4) : 102 - 102
  • [9] Safety, pharmacokinetics, and efficacy of belantamab mafodotin monotherapy in Japanese patients with relapsed or refractory multiple myeloma: DREAMM-11
    Shinsuke Iida
    Kazutaka Sunami
    Yuko Mishima
    Taku Fujii
    Hitomi Kato
    Takumi Terao
    Yuki Matsuzawa
    Mari Matsubara
    Timothy Crossman
    Brandon E. Kremer
    Ira Gupta
    International Journal of Hematology, 2023, 118 : 596 - 608
  • [10] Single-agent belantamab mafodotin for relapsed/refractory multiple myeloma: analysis of the lyophilised presentation cohort from the pivotal DREAMM-2 study
    Paul G. Richardson
    Hans C. Lee
    Al-Ola Abdallah
    Adam D. Cohen
    Prashant Kapoor
    Peter M. Voorhees
    Axel Hoos
    Karrie Wang
    January Baron
    Trisha Piontek
    Julie Byrne
    Scott Richmond
    Roxanne C. Jewell
    Joanna Opalinska
    Ira Gupta
    Sagar Lonial
    Blood Cancer Journal, 10
12345